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Abstract: The risk for developing type 2 diabetes (T2DM) is greater among obese individuals. 
Following onset of the disease, patients with T2DM become more likely to be afflicted with 
diabetic micro- and macrovascular complications. Decreasing body weight has been shown to 
lower glycosylated hemoglobin and improve other metabolic parameters in patients with T2DM. 
Medications used to lower blood glucose may increase body weight in patients with T2DM and 
this has been repeatedly shown to be the case for conventional, human insulin formulations. 
Insulin detemir is a neutral, soluble, long-acting insulin analog in which threonine-30 of the 
insulin B-chain is deleted, and the C-terminal lysine is acetylated with myristic acid, a C14 
fatty acid chain. Insulin detemir binds to albumin, a property that enhances its pharmacokinetic/
pharmacodynamic profile. Results from clinical trials have demonstrated that treatment with 
insulin detemir is associated with less weight gain than either insulin glargine or neutral protamine 
Hagedorn insulin. There are many potential reasons for the lower weight gain observed among 
patients treated with insulin detemir, including lower risk for hypoglycemia and therefore 
decreased defensive eating due to concern about this adverse event, along with other effects that 
may be related to the albumin binding of this insulin that may account for lower within-patient 
variability and consistent action. These might include faster transport across the blood–brain 
barrier, induction of satiety signaling in the brain, and preferential inhibition of hepatic glucose 
production versus peripheral glucose uptake. Experiments in diabetic rats have also indicated 
that insulin detemir increases adiponectin levels, which is associated with both weight loss and 
decreased eating.
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Introduction
The population of overweight (body mass index [BMI] 25.0–29.9 kg/m2) and obese 
(BMI $ 30 kg/m2) individuals in the USA continues to increase, and these conditions 
are a major clinical problem with respect to the development and treatment of type 2 
diabetes mellitus (T2DM).1,2 It has been estimated that 82%–87% of individuals with 
diabetes are either overweight or obese,3 and it is also well known that cardiovascular 
risk factors beyond hyperglycemia, such as overweight/obesity, elevated blood pressure, 
and abnormal lipid levels, are important predictors of all-cause and cardiovascular 
mortality in patients with diabetes.4 Weight gain is also an important concern as 
a potential side effect of treatment for patients with T2DM receiving certain oral 
therapies or insulin;5,6 it has been suggested that the increase in body weight associated 
with antidiabetes therapy may blunt the clinical benefit of improved glycemic control 
associated with such therapy.7 Weight gain in patients with T2DM can also contribute 
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to patient frustration with treatment, may negatively impact 
their adherence to therapeutic regimens, and could deter their 
motivation to adhere to lifestyle modifications.8
Results from numerous clinical trials have demonstrated 
that weight reduction decreases cardiovascular risk factors, 
and it is likely that this benefit extends to patients with 
T2DM.9–12 In addition, multiple studies have shown that 
obesity is an important contributor to insulin resistance and 
thus has the potential to blunt the benefit of oral secretagogues 
and insulin therapy.13–15 Data from the weight loss arm of 
the   Trials of Hypertension Prevention study showed that 
even modest weight loss (−4.4 kg at 6 months, −2.0 kg at 
18 months, and −0.2 kg at 36 months) led to clinically sig-
nificant long-term reductions in blood pressure (BP) (−3.7, 
−1.8, and −1.3 mm Hg for systolic BP; and −2.7, −1.3, 
and −0.9 mm Hg for diastolic BP at 6, 18, and 36 months, 
respectively) and reduced risk for hypertension by 42% at 
6 months, 22% at 18 months, and 19% at 36 months. Subjects 
who lost $4.5 kg at 6 months and maintained this weight 
reduction for the next 30 months had the greatest reduction 
in BP and a 65% reduction in the risk for hypertension.16 
A 2-year weight reduction study (via weight-loss diets) in 
moderately obese individuals showed that a diet that leads to 
weight loss favorably modifies metabolic parameters related 
to cardiovascular risk (ie, low density lipoprotein choles-
terol, triglycerides, high-density lipoprotein cholesterol).17 
One-year results from the Action for Health in Diabetes 
(Look AHEAD) trial showed that clinically significant weight 
loss in patients with T2DM was associated with improved 
glycemic control and an improved cardiovascular risk 
profile.18 Recently published 4-year results from the Look 
AHEAD trial indicated that patients receiving intensive 
lifestyle intervention had a significantly greater percentage 
of weight loss than participants who received only diabetes 
education (−6.15% versus −0.88%, P , 0.001), greater 
reductions in glycosylated hemoglobin (A1C) levels (−0.36% 
versus −0.09%, P , 0.001), greater decreases in systolic 
and diastolic BP and triglycerides, and significantly greater 
increases in high density lipoprotein cholesterol.9
The results from Look AHEAD and other trials are 
consistent with the suggestion that the care of individu-
als with T2DM may be too glucocentric and that patient 
management must consider a wider range of factors 
that may contribute to the development of micro- and 
  macrovascular disease, including obesity, hypertension, and 
dyslipidemia.18,19 The benefit of a more multifaceted and 
integrated approach to the management of patients with 
T2DM that simultaneously addressed multiple cardiovascular 
risk factors has been demonstrated by results from the 
Steno-2 trial.20 In this study, 160 patients with T2DM and 
microalbuminuria received either intensive multifaceted 
treatment or conventional therapy. Patients in Steno-2 were 
followed for 13.3 years; over this period, 24 patients in the 
intensive therapy group died versus 40 in the conventional 
treatment group (hazard ratio [HR] = 0.54, P = 0.02). Intensive 
therapy was associated with a lower risk of death from 
cardiovascular causes (HR = 0.43, P = 0.04), cardiovascular 
events (HR = 0.41, P , 0.001), diabetic nephropathy (relative 
risk [RR] = 0.44, P = 0.004), and requirement for retinal 
photocoagulation (RR = 0.45, P = 0.02).20
While it has been shown to improve the long-term 
prognosis in patients with T2DM, treatment with insulin 
therapy is complicated by weight gain, which may delay 
initiation of this treatment in patients not maintaining 
glycemic control on oral drugs and/or intensification of 
dosing to maintain control in those already receiving insulin.21 
Because insulin detemir is associated with less weight gain 
than insulin glargine,22,23 the aim of this paper is to review 
the role of insulin detemir in the treatment of patients with 
T2DM, with a focus on efficacy in obese patients and effects 
on body weight.
Cost of agents is always a consideration. However, the 
question of cost is a complex topic requiring a thorough 
balance between direct and indirect costs and short term 
versus long-term costs. Such an analysis is beyond the scope 
of this paper. However, reports do suggest a cost advantage of 
long-acting insulin analogs over neutral protamine Hagedorn 
(NPH) insulin.24
Insulin therapy and body weight
A very large percentage of patients with T2DM ultimately 
require insulin to maintain control over blood glucose, due 
to the progressive nature of the disease and the exhaustion 
of pancreatic β-cells.25,26 Results from 61,890 patients with 
T2DM indicated that after more than 20 years following 
diagnosis, 50% were receiving insulin.27 Insulin, when prop-
erly dosed, is the most effective drug currently available to 
achieve optimal glycemic control and avoid long-term disease 
complications. Although there is no maximum dose or ceiling 
effect, insulin treatment is commonly associated with weight 
gain brought on by multiple factors. Mechanisms believed to 
be involved in weight gain associated with insulin therapy 
include reduced glycosuria and associated loss of caloric 
intake; stimulation of fatty acid conversion into triglycerides in 
adipose tissue, which favors an increase in adipose mass; 
and inhibition of muscle proteolysis, resulting in a positive 
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  nitrogen balance and an increase in lean mass.28 The anabolic 
effect of insulin (inhibition of muscle proteolysis) is reflected 
by the fact that patients with diabetes who are receiving insulin 
gain lean as well as fat mass. Nevertheless, results from one 
evaluation indicated that nearly two-thirds of the weight gain 
associated with insulin treatment was fat mass.29 Defensive 
snacking behaviors, driven by fears of hypoglycemia, can also 
contribute to weight gain in patients using insulin.30
The type of insulin used for treatment also influences 
weight gain. For example, results from multiple clinical tri-
als have demonstrated that patients with T2DM treated with 
NPH insulin gained between 0.3 and 2.8 kg.31–33 The devel-
opment of insulin analogs has the potential to significantly 
ameliorate the weight gain associated with basal insulin 
therapy; this has been shown most clearly and consistently for 
insulin detemir. In fact, although improvements in A1C 
were not significantly different between patients treated 
with insulin glargine (−1.46% ± 1.09%) or insulin detemir 
(−1.54% ± 1.11%, between group P = 0.149), those treated with 
insulin detemir had significantly less weight gain (difference: 
0.77 kg, P , 0.001).23 Similar differences in weight gain were 
found in earlier studies as well;22 however, no studies have yet 
been designed to assess whether such lower amounts of weight 
gain can translate into improvements in long-term outcomes, 
such as morbidity and mortality. The evidence that exists 
from both the Diabetes Control and Complications Trial and 
the UK Prospective Diabetes Study supports the concept 
that better glucose control does relate to less morbidity and 
mortality,34 although there is no established link between 
improved morbidity and mortality and insulin detemir.
Insulin detemir
Insulin detemir is a neutral, soluble, long-acting insulin analog 
in which threonine is deleted from position B30 of the insulin 
B-chain and the ε-amino group of lysine B29 is acetylated 
with a 14-carbon myristoyl fatty acid (Figure 1).35–37 This 
fatty acid modification allows insulin detemir to reversibly 
bind to the long-chain fatty acid binding sites of albumin, 
and this contributes to the extended time action profile for 
this analog.38 Insulin detemir is soluble at neutral pH, which 
enables it to remain in a liquid form following subcutaneous 
injection. This property contrasts with NPH insulin, which 
is a preformed crystalline precipitate suspension, and insulin 
glargine, which is an acidic solution that precipitates in the 
subcutaneous tissue after administration. The solubility of 
insulin detemir may contribute to its low variability in phar-
macokinetic and pharmacodynamic properties.35,36
Pharmacokinetics/Pharmacodynamics
Once-daily insulin detemir provides 24-hour control over 
blood glucose equivalent to that for insulin glargine, the 
other long-acting insulin analog.39 Insulin detemir admin-
istered twice daily reaches steady state after the second 
injection and shows a constant metabolic effect over time 
under steady-state conditions.40 It has a duration of action 
of about 24 hours and concentrations in blood that increase 
with dose (Figure 2).41–43 The effects of body weight on 
the pharmacokinetics are not known due to the fact that 
published studies concerned with studying pharmacody-
namics of insulin detemir have typically included nonobese 
subjects and because insulin detemir was dosed on the basis 
of body weight.40,44
Multiple studies have provided clear support for a once-
daily dosing regimen with insulin detemir. For example, 
results from the European cohort of the Predictable Results 
and Experience in Diabetes through Intensification and 
Control to Target: an International Variability Evaluation 
(PREDICTIVETM) study showed that switching from twice 
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Figure 1 Structure of insulin detemir.37
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daily NPH insulin to once daily insulin detemir resulted 
in significant 12-week reductions in A1C (P , 0.001).45 
A 52-week trial included patients with T2DM who were 
receiving oral antidiabetes drugs and insulin detemir once or 
twice daily as needed or once daily insulin glargine, reported 
that A1C decreased from 8.6% to 7.1% with insulin detemir 
among patients who completed the study, whether or not they 
received one or two doses per day, and from 8.6% to 7.1% 
for all patients who received insulin glargine.22
Clinical experience with basal insulin 
analogs: focus on weight gain
Results from multiple controlled clinical trials of patients 
with T2DM have shown that insulin detemir results in less 
weight gain than NPH insulin when used as monotherapy, 
when added to oral antidiabetes drugs, and when employed 
as part of basal bolus therapy.46–48 Additional controlled 
clinical studies have also demonstrated that insulin detemir 
is associated with less weight gain than insulin glargine 
when used as part of basal bolus treatment49,50 and when 
added to oral antidiabetes drugs.22 Results from a 20-week 
comparison of insulin detemir versus NPH insulin added 
to oral agents indicated that weight gain was 1.2, 0.7, and 
1.6 kg with morning detemir, evening detemir, and NPH 
insulin, respectively (P = 0.005 for evening detemir versus 
NPH insulin).48 Another comparison of insulin detemir versus 
NPH insulin, each combined with mealtime insulin aspart for 
26 weeks in overweight patients (mean BMI = 31.8 kg/m2), 
indicated that weight gain was 0.4 kg for insulin detemir 
and 1.9 kg for NPH insulin (P # 0.0001).46 A comparison of 
insulins detemir and glargine as part of basal bolus therapy 
in patients with T2DM indicated that weight gain was 
1.2 kg for insulin detemir versus 2.7 kg for insulin glargine 
at the end of 26 weeks of treatment (P = 0.001).50 Results 
from a 52-week, multinational, open-label, parallel-group, 
noninferiority, treat-to-target trial comparing both once and 
twice daily insulin detemir with once daily insulin glargine in 
a basal plus regimen with oral antidiabetes drugs in patients 
with T2DM indicated that mean weight gain at 52 weeks 
was significantly lower among those who received insulin 
detemir than insulin glargine (3.0 versus 3.9 kg, P , 0.001), 
and further analysis revealed there was even less weight 
gain among those who received insulin detemir once a day 
(2.3 kg).22 Therefore, once daily dosing with insulin detemir 
may be advantageous in obese or overweight patients with 
T2DM to minimize weight gain.
The effects of insulin detemir on weight gain have been 
studied across a wide range of patients, including those who 
are overweight or obese. Meta-analysis of five parallel group 
randomized controlled trials of at least 20 weeks’ duration 
that compared once daily evening insulin glargine or insulin 
detemir with a common comparator, NPH insulin (evening 
administration), showed that patients with T2DM (n = 2092) 
who received evening insulin detemir gained significantly 
less weight (−1.22 kg) than those treated with insulin glargine 
(−0.29 kg, P = 0.010).51 Importantly, this analysis focused 
on insulin naïve, T2DM patients poorly controlled with oral 
antidiabetes drugs, which are the patients most likely to be 
switched to insulin therapy in clinical practice. The beneficial 
effects of insulin detemir on weight change appear greatest 
in patients with high body weight or BMI at the initiation 
of treatment.33,52 Results from the Treat to target with once-
daily Insulin Therapy: Reduce AIC by Titrating Effectively 
(TITRATETM) study, in which insulin detemir was added to 
oral antidiabetes drugs,   indicated that body weight changes 
from baseline after insulin detemir treatment were related 
to baseline BMI. Patients with baseline BMI # 25 kg/m2 
experienced weight increases from 1.35 to 1.38 kg and those 
with baseline BMI . 40 kg/m2 at baseline experienced weight 
decreases from −0.14 to −0.33 kg.53
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Figure 2 Pharmacodynamic profile for insulin detemir (glucose infusion rate in euglycemic glucose clamp experiments).42 
Note: Reprinted with permission from John wiley and Sons. 
Abbreviation: GIR, glucose infusion rate.
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Pooled analyses have also investigated whether weight 
changes with insulin detemir were linked to baseline BMI 
in patients with diabetes. Data were collected from three 
randomized, parallel group trials of 22–26 weeks   duration 
that included 1416 patients aged $65 years and 880 patients 
aged 18–64 years, all of whom were treated with insulin.54 
At the end of the study, A1C control and fasting plasma 
glucose were similar for both age groups, regardless of 
whether they received insulin detemir or NPH insulin. 
  However, both older patients (mean weight at baseline: 
insulin detemir = 81 kg, NPH insulin = 79 kg) and younger 
patients (mean weight at baseline: insulin detemir = 85 kg, 
NPH insulin = 85 kg) gained statistically significantly less 
body weight with insulin detemir than NPH insulin (0.69 
versus 1.62 kg for older persons, P , 0.001; 0.80 versus 
1.93 kg for younger persons, P , 0.001).54 A report of data 
pooled from two randomized, parallel group trials of 22 and 
24 weeks’ duration that included 900 insulin treated patients 
with T2DM who had their treatment intensified to basal bolus 
therapy.47 Patients received once or twice daily insulin detemir 
or NPH insulin in conjunction with insulin aspart or human 
soluble insulin at mealtimes. Although there was no between 
group   difference in A1C, indicating comparable glycemic 
control, patients treated with insulin detemir had minimal 
weight gain (mean , 1 kg), regardless of their BMI at entry 
(estimated slope −0.032); whereas, in patients treated with 
NPH insulin, weight gain increased as baseline BMI rose 
(estimated slope 0.075, P = 0.025). Patients receiving NPH 
insulin with BMI . 35 kg/m2 gained the most weight (mean 
of ∼2.4 kg) while insulin detemir-treated patients with the 
same BMI range lost weight (∼0.5 kg).47
Can reduced risk for hypoglycemia 
explain decreased weight gain  
with insulin detemir?
Although insulin glargine can also provide less of a risk 
for hypoglycemia than NPH insulin,55 insulin detemir has 
even less of an impact on weight gain than other basal or 
intermediate-acting insulin formulations, and therefore it 
is important to discuss mechanisms that allow this to be 
manifested. Several potential mechanisms that have been 
proposed are addressed below.
Reduced risk of hypoglycemia with insulin detemir, 
coupled with a more consistent and reliable delivery of the 
desired dose than is available with traditional basal insulin, 
such as NPH insulin, has been proposed as a possible 
mechanism that could decrease defensive snacking by 
patients and help to limit weight gain.56 Insulin detemir has 
been repeatedly shown to have lower risk for hypoglycemia 
than NPH insulin when administered either once48 or 
twice33 daily. A recent meta-analysis has shown that insulin 
detemir is associated with significantly lower overall risk for 
severe hypoglycemia versus NPH insulin (RR = 0.74, 95% 
confidence interval [CI] = 0.58−0.96, P , 0.05). Insulin 
detemir is also associated with significantly lower risk for 
nocturnal hypoglycemia versus NPH insulin (RR = 0.92, 
95% CI = 0.85–0.98, P , 0.05).57 Results from another 
meta-analysis of studies comparing insulin detemir with 
NPH insulin that focused on patient age indicated that the 
RR for all hypoglycemic episodes (insulin detemir/NPH 
insulin) was 0.59 (95% CI = 0.42–0.83) for older persons and 
0.75 (95% CI = 0.59–0.96) for younger patients.54 Results 
from the TITRATE study, which had aggressive glucose 
targets, indicated that overall rates of hypoglycemia episodes 
were low and were comparable between insulin detemir 
treatment groups (7.73 and 5.27 events/subject/year for 
the 70–90 mg/dL and 80–110 mg/dL fasting plasma target 
groups, respectively). A single event of major hypoglycemia 
was reported in the 70–90 mg/dL target group.53 Results from 
the PREDICTIVE BMI study showed that the incidence of 
hypoglycemia was lower with insulin detemir versus NPH 
insulin (RR = 0.62 for all events and 0.43 for nocturnal 
events, P , 0.0001 for both comparisons).46
Although the earlier described studies and meta-
analysis show that the risk for hypoglycemia is significantly 
decreased with insulin detemir versus NPH insulin, and it 
is reasonable to expect that this may result in less defensive 
eating, decreased weight gain with insulin detemir is not 
completely explained by decreased risk for hypoglycemia. 
A 26-week, randomized, multicenter, open label, parallel 
group trial compared glycemic control, hypoglycemia, and 
weight change between insulin detemir and NPH insulin 
(administered in the morning and evening) in a total of 
476 insulin naïve patients with T2DM who were also being 
treated with one or two oral antidiabetes drugs.58 Weight 
gain data from this study were analyzed as a function of 
hypoglycemia frequency. Weight gain with insulin detemir 
was 1.2 kg versus 2.8 kg with NPH insulin (P , 0.001), 
and the overall risk of hypoglycemia was 47% lower with 
insulin detemir (P , 0.001). No significant relationship 
between hypoglycemia and weight gain was seen with insulin 
detemir (P = 0.2), but such a relationship was demonstrated 
for NPH insulin (P = 0.003). These results are consistent with 
observations from healthy volunteers showing that insulin 
detemir treatment results in increased awareness during 
hypoglycemia.59 Thus, results from these two studies, when 
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considered together, suggest that decreased awareness of 
hypoglycemia and less defensive eating cannot fully explain 
less weight gain with insulin detemir.
Alternative explanations  
for decreased weight gain  
with insulin detemir
There are several potential reasons for decreased weight gain 
with insulin detemir beyond a potential reduction in defensive 
eating secondary to decreased risk for hypoglycemia.
Hepatic influences
Due to its novel method of prolonging action via albumin 
binding, insulin detemir may influence hepatic glucose 
metabolism to a greater extent than peripheral tissues. The 
association of insulin detemir with nonesterified fatty acid 
binding sites on albumin may limit its transfer from the 
  circulation into the extravascular extracellular space in adipose 
tissue and muscle, due to the capillary endothelial cell barrier. 
In the liver, the open sinusoids may expose hepatocytes to 
insulin detemir, enabling it to have a greater effect in the liver 
than in peripheral tissues. Results from a study in humans 
indicated that at and below plasma glucose concentrations of 
54 mg/dL, suppression of endogenous glucose production was 
greater with insulin detemir than with NPH insulin, whereas 
stimulation of peripheral glucose uptake was greater with NPH 
insulin than with insulin detemir.60 These authors suggested 
that decreased peripheral glucose uptake may contribute to 
lower weight gain with insulin detemir versus NPH insulin.
CNS influences
Another possibility that might explain less weight gain with 
insulin detemir versus other insulins is that it facilitates the 
actions of central nervous system mechanisms associated with 
satiety. Insulin detemir may be more effective than regular 
human insulin in communicating satiety signals within the 
central nervous system due to increased ability to cross the 
blood–brain barrier resulting from albumin binding. Results 
from a study in which insulin was administered intranasally 
to healthy subjects indicated that this treatment, which 
increases insulin levels in the cerebrospinal fluid, produced 
significant elevations in serum leptins and weight loss in 
men.61 This suggests that insulin may provide a negative 
feedback signal that regulates adiposity. Results from studies 
in human patients who received insulin injections indicated 
that this treatment can rapidly alter electroencephalographic 
activity.62 This effect suggests that insulin can influence 
hypothalamic circuits involved in satiety and feeding.61 
A study in 15 healthy volunteers showed that a bolus injection 
of insulin detemir during hyperinsulinemic-euglycemic 
clamp produced a change in the electroencephalogram not 
observed after injection of regular human insulin.62 Results 
from this study also showed that insulin detemir significantly 
decreased subsequent food intake by about 300 kcal versus 
regular human insulin (P , 0.04). However, it is important 
to note that other recent studies have suggested that insulin 
detemir is not transported across the blood–brain barrier,63 
and that acute intracerebroventricularly injected human 
insulin does not significantly inhibit food intake in rats.64
Results from studies in experimental animals also support 
the suggestion that actions other than decreasing the risk of 
hypoglycemia may be involved in the effects of insulin detemir 
on body weight in patients with T2DM. It has been shown that 
administration of insulin detemir to Zucker diabetic fatty rats 
(an animal model for diabetes) results in smaller increases in 
fat mass than either insulin glargine or NPH insulin.65 This 
result prompted the authors of this study to speculate that the 
reduced weight gain in patients treated with insulin detemir 
versus other intermediate or long-acting insulins to be due 
to decreased adiposity. A second study in the same strain of 
diabetic rats showed further that insulin detemir increases 
adiponectin levels to a greater extent than NPH insulin.66 It is 
well known that adiponectin is decreased in obesity, and that 
higher adiponectin concentrations are associated with both 
weight loss and anorexia.67 Both adiponectin and leptin are 
derived from adipose tissue and they influence food intake, 
insulin resistance, and lipolysis.68,69 Comparison of the effects 
of insulin detemir and human insulin on 3T3-L1 preadipocytes 
indicated that human insulin, but not insulin detemir, was 
associated with clonal expansion and that insulin detemir 
had reduced adipogenic effects versus human insulin.70 
Thus, while the mechanisms underlying lower weight gain 
with insulin detemir versus other insulins are not clear, it is 
reasonable to speculate that they may involve albumin binding, 
preferential activity in brain and liver, and favorable effects on 
adipocytes.71 Further studies are needed to determine which, 
of these or other mechanisms, underlie the positive effects of 
insulin detemir versus other insulin formulations.
Conclusion
Most patients with T2DM progress to treatment with insulin. 
The benefit of better glucose control offered by insulin can be 
offset by the higher weight gain and the hypoglycemia that 
occurs most commonly with human insulins than some analog 
formulations. This may lead to poor adherence to treatment by 
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some patients. Results from multiple clinical trials with insulin 
detemir have shown that its use results in less weight gain than 
older types of insulin, including NPH insulin. In addition, 
insulin detemir causes less weight gain among patients with 
high baseline weight or BMI. This trend for less weight gain 
may have a clinical impact on an individual basis. Multiple 
mechanisms may contribute to less weight gain with insulin 
detemir versus other insulins, and they all may be linked to 
the unique structure of the molecule, which includes a C14 
fatty acid chain that enables binding to albumin.
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